title: The relationship between the systemic inflammatory response and survival in patients with transitional cell carcinoma of the urinary bladder.
abstract: The relationship between tumour stage, grade, elevated C-reactive protein concentration (<10/>10 mg l(-1)), adjuvant therapy and survival was examined in patients with biopsy proven bladder cancer (n=105). On multivariate analysis stage (HR 3.37, 95% CI 1.37-8.29, P=0.008), grade (HR 2.01, 95% CI 1.14-3.57, P=0.017) and preoperative C-reactive protein (HR 3.31, 95% CI 1.09-10.09, P=0.035) were independently associated with cancer-specific survival.
authors.affiliation: University Department of Surgery, Royal Infirmary, Glasgow G31 2ER, Scotland, UK. m.hilmy@doctors.net.uk
authors.forename: M
authors.initials: M
authors.lastname: Hilmy
authors.forename: J M S
authors.initials: JM
authors.lastname: Bartlett
authors.forename: M A
authors.initials: MA
authors.lastname: Underwood
authors.forename: D C
authors.initials: DC
authors.lastname: McMillan
mesh_terms: D000368:Aged; D000704:Analysis of Variance; D002097:C-Reactive Protein / Q000378:metabolism; D002295:Carcinoma, Transitional Cell / Q000097:blood / Q000150:complications* / Q000401:mortality* / Q000473:pathology / Q000628:therapy; D016001:Confidence Intervals; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D016017:Odds Ratio; D016019:Survival Analysis; D018746:Systemic Inflammatory Response Syndrome / Q000097:blood / Q000150:complications* / Q000401:mortality*; D001749:Urinary Bladder Neoplasms / Q000097:blood / Q000150:complications* / Q000401:mortality* / Q000473:pathology / Q000628:therapy
chemical_list: D002097:C-Reactive Protein
references.citation: Eur Urol. 2004 Feb;45(2):176-81
references.pmid: 14734003
references.citation: Br J Cancer. 2003 Sep 15;89(6):1028-30
references.pmid: 12966420
references.citation: Eur J Cancer. 1981 Feb;17(2):251-5
references.pmid: 7262162
references.citation: Br J Urol. 1995 Oct;76(4):470-4
references.pmid: 7551884
references.citation: Int J Cancer. 1997 Jul 3;72(1):149-54
references.pmid: 9212236
references.citation: J Nutr. 1998 Aug;128(8):1355-60
references.pmid: 9687556
references.citation: Nutr Cancer. 1998;31(2):101-5
references.pmid: 9770720
references.citation: Br J Cancer. 1999 Mar;79(9-10):1392-8
references.pmid: 10188881
references.citation: Nutr Cancer. 2000;37(1):36-40
references.pmid: 10965517
references.citation: Ann Intern Med. 2000 Oct 17;133(8):622-34
references.pmid: 11033592
references.citation: Lancet. 2001 Feb 17;357(9255):539-45
references.pmid: 11229684
references.citation: J Urol. 2002 Mar;167(3):1475-81
references.pmid: 11832773
references.citation: Curr Oncol Rep. 2002 May;4(3):250-5
references.pmid: 11937016
references.citation: Nature. 2002 Dec 19-26;420(6917):860-7
references.pmid: 12490959
references.citation: Br J Surg. 2003 Feb;90(2):215-9
references.pmid: 12555298
references.citation: Ann Surg. 2003 Aug;238(2):197-202
references.pmid: 12894012
references.citation: BJU Int. 2003 Sep;92(4):393-9
references.pmid: 12930428
references.citation: Br J Cancer. 2004 May 4;90(9):1707-9
references.pmid: 15150596